Previous research has elucidated that this synthetically engineered probiotic yeast has the capacity to engage with the PD-1/PD-L1 pathway, thereby alleviating intestinal tumor burden in a mouse model of colorectal cancer that is refractory to standard immune checkpoint inhibitor (ICI) therapy (Wong and Yu, 2023). Here, CD274 is linked to colorectal cancer.